• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Accel Entertainment, Inc.
Bf and Crumrine Invest Grade Pref ETF
BlackRock TCP Capital Corp. - Closed End Fund
Grifols, S.A. - American Depositary Shares
Ibero Mng Corp
LifeMD, Inc. - Common Stock
Marquette National Corp
Pmv Consumer Acquisition Corp
Sigma Additive Solutions, Inc. - Common Stock
TripAdvisor
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

FibroBiologics, Inc. - Common Stock (NQ:FBLG)

0.9500 -0.0700 (-6.86%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 111,923
Open 1.020
Bid (Size) 0.9001 (100)
Ask (Size) 0.9999 (1,200)
Prev. Close 1.020
Today's Range 0.9500 - 1.020
52wk Range 0.6201 - 9.598
Shares Outstanding 38,262,586
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
September 25, 2026
From RedChip Companies, Inc. (Media Suite)
Via ACCESS Newswire
News headline image
Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications
September 08, 2026
Learn how FibroBiologics is developing an off-the-shelf therapeutic platform designed to harness the regenerative and immune-modulating properties of fibroblasts Management to discuss the ongoing Phase... 
From RedChip Companies, Inc. (Media Suite)
Via ACCESS Newswire

Performance

52-Week Range 90.1% below 52-week high
0.9500
0.6252W Low 9.6052W High
1 Week 23.4% below 1-week high
0.881W Low 1.241W High

FibroBiologics, Inc. - Common Stock (FBLG) traded between $0.62 and $9.60 over the past 52 weeks and last traded at $0.95, 90.1% below its 52-week high. Over the past week it ranged between $0.88 and $1.24.

Past 12 Months
+0.6%
-30.1%
+51.5%
-33.6%
-80.2%
-89.1%
1W +$0.01
1M -$0.41
3M +$0.32
6M -$0.48
YTD -$3.85
1Y -$7.78

FBLG was -89.1% over the past year, -33.6% over six months, -80.2% year to date, +0.6% in the last week.

12 Months vs Market
FBLG
-89.1%
DIA
+10.4%
SPY
+12.2%
QQQ
+14.1%
IWM
+10.6%

Over the past 12 months FBLG returned -89.1% versus DIA (Dow) +10.4%, SPY (S&P 500) +12.2%, QQQ (Nasdaq 100) +14.1% and IWM (Russell 2000) +10.6%.

Volume & Liquidity 0.51× 3-mo avg
Today 111,923 3-mo avg 218.0K
1W
180.5K
1M
153.6K
3M
218.0K
6M
215.2K
YTD
242.4K
1Y
215.8K

FBLG most recently traded 111,923 shares against a 3-month average daily volume of 218.0K.

More News

Read More
News headline image
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
June 22, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
June 16, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
June 03, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial ↗
June 03, 2026
Via Benzinga
News headline image
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
May 22, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
May 18, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
May 11, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics CEO Issues Letter to Shareholders
May 05, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
May 04, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
May 04, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
April 30, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
April 30, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Compliant with All Nasdaq Listing Requirements
April 20, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity
April 10, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Closing of $3 Million Public Offering
April 02, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Wednesday? ↗
April 01, 2026
Via Chartmill
News headline image
FibroBiologics Announces Pricing of $3 Million Public Offering
March 31, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
Top movers in Tuesday's after hours session ↗
March 31, 2026
Via Chartmill
News headline image
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
March 31, 2026
From FibroBiologics, Inc.
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
March 31, 2026
Via Chartmill
Which stocks are experiencing notable movement on Tuesday? ↗
March 31, 2026
Via Chartmill
The market is filled with gapping stocks in Tuesday's session. ↗
March 31, 2026
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
March 25, 2026
Via Chartmill

Frequently Asked Questions

Is FibroBiologics, Inc. - Common Stock publicly traded?
Yes, FibroBiologics, Inc. - Common Stock is publicly traded.
What exchange does FibroBiologics, Inc. - Common Stock trade on?
FibroBiologics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for FibroBiologics, Inc. - Common Stock?
The ticker symbol for FibroBiologics, Inc. - Common Stock is FBLG on the Nasdaq Stock Market
What is the current price of FibroBiologics, Inc. - Common Stock?
The current price of FibroBiologics, Inc. - Common Stock is 0.9500
When was FibroBiologics, Inc. - Common Stock last traded?
The last trade of FibroBiologics, Inc. - Common Stock was at 10/23/26 04:00 PM ET
What is the market capitalization of FibroBiologics, Inc. - Common Stock?
The market capitalization of FibroBiologics, Inc. - Common Stock is 36.35M
How many shares of FibroBiologics, Inc. - Common Stock are outstanding?
FibroBiologics, Inc. - Common Stock has 36M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap